News
Nextstellis® Oral Contraceptive Now Available in the United States
21 Jun 2021
US commercial launch of NEXTSTELLIS® a new oral contraceptive with a novel estrogen.
Learn more
Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published
27 May 2021
NEXTSTELLIS® has been granted marketing exclusivity as a new chemical entity (NCE) from the US Food and Drug Administration (FDA)
Learn more
FDA approval of novel oral contraceptive NEXTSTELLIS®
16 Apr 2021
US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive NEXTSTELLIS®
Learn more
U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive
16 Apr 2021
Mayne Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved NEXTSTELLIS.
Learn more
New data on NEXTSTELLIS® presented at ISSWSH conference
8 Mar 2021
New data showing treatment with NEXTSTELLIS™, a novel, investigational combined oral contraceptive
Learn more
Mayne Pharma 2021 Half Year Results Media Release
24 Feb 2021
Mayne Pharma 2021 Half Year Results Media Release
Learn more
Microgestin® 24 Fe tablets launch in the United States
7 Jan 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of MICROGESTIN® 24 FE
Learn more